LOGIN  |  REGISTER
Assertio

Phathom Pharmaceuticals (NASDAQ: PHAT) Stock Quote

Follow Insider Trades Visit website
Last Trade: US$10.62 -0.24 -2.21
Volume: 550,459
5-Day Change: -18.12%
YTD Change: -5.35%
Market Cap: US$603.220M

Latest News From Phathom Pharmaceuticals

September 5, 2023
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: Morgan Stanley 21 st Annual Global Healthcare Conference in New York City. Management will... Read More
August 21, 2023
Phathom Pharmaceuticals Announces Submission of Six-Month Stability Data in Support of Erosive GERD New Drug Application
Six-month stability data remain more than 10x below the acceptable intake limit set by the U.S. Food and Drug Administration (FDA) and continue to support the requested product shelf life Submission of six-month stability data satisfies Phathom's stability data submission requirements for Erosive GERD New Drug Application (NDA) for vonoprazan with a Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023... Read More
August 10, 2023
Phathom Pharmaceuticals Reports Second Quarter 2023 Results
Prior Approval Supplement (PAS) for VOQUEZNA ® TRIPLE PAK ® and VOQUEZNA ® DUAL PAK ® assigned a Prescription Drug User Fee Act (PDUFA) goal date of October 30, 2023 by the U.S. Food and Drug Administration (FDA) U.S. commercial launch for H. pylori and Erosive GERD planned for Q4 2023 Successfully completed Phase 3 PHALCON-NERD-301 trial for Non-Erosive GERD; regulatory submission on track to occur by year-end FLORHAM PARK,... Read More
June 12, 2023
Phathom Pharmaceuticals Announces FDA Acceptance of NDA Resubmission for Erosive GERD
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023 Combined launch of vonoprazan for Erosive GERD and H. pylori indications planned for Q4 2023, if approved FLORHAM PARK, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced that the U.S. Food... Read More
June 9, 2023
Phathom Pharmaceuticals Announces Closing of Underwriters’ Option to Purchase Additional Shares in Connection with Public Offering of Common Stock
FLORHAM PARK, N.J., June 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the closing of the sale of an additional 1,668,750 shares of common stock at a public offering price of $11.75 per share pursuant to the exercise in full of the underwriters’ option to purchase... Read More
June 1, 2023
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: 2023 Jefferies Healthcare Conference in New York City, NY, with a scheduled fireside chat on... Read More
May 23, 2023
Phathom Pharmaceuticals Announces Pricing of Public Offering of Common Stock
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today the pricing of its underwritten public offering of 11,125,000 shares of its common stock at a price to the public of $11.75 per share. The gross proceeds to Phathom from the offering, before... Read More
May 23, 2023
Phathom Pharmaceuticals Announces Proposed Public Offering of Common Stock
FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. In addition, Phathom intends to grant the underwriters a... Read More
May 23, 2023
Phathom Pharmaceuticals Resubmits Erosive GERD New Drug Application to FDA
Anticipated FDA action date in Q4 2023; if approved, combined launch for Erosive GERD and H. pylori indications planned before year end If approved, vonoprazan would be the first innovative acid suppressant from a new drug class approved for the treatment of Erosive GERD in the U.S. in over 30 years FLORHAM PARK, N.J., May 23, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company... Read More
May 10, 2023
Phathom Pharmaceuticals Reports First Quarter 2023 Results
FLORHAM PARK, N.J., May 10, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported financial results for the first quarter of 2023 and provided updates on recent regulatory progress. “This quarter, we made remarkable progress advancing mission-critical priorities that position... Read More
May 9, 2023
Phathom Pharmaceuticals Presents New Data at Digestive Disease Week® (DDW) 2023
Higher H. pylori eradication rates demonstrated with vonoprazan-based regimens vs. lansoprazole triple therapy, regardless of different baseline demographics and clinical characteristics Meta-analysis shows potassium-competitor acid blockers (PCABs), including vonoprazan, provide a longer duration of pH >4, higher predicted Erosive GERD healing rates, and lower probabilities of failure to achieve healing FLORHAM PARK, N.J.,... Read More
April 12, 2023
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
FLORHAM PARK, N.J., April 12, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, announced today that members of its management team will participate in the following upcoming investor conferences: 22nd Annual Needham Virtual Healthcare Conference , including a scheduled fireside chat on... Read More
April 4, 2023
Phathom Pharmaceuticals Announces Regulatory Update and Plans for 2023 Erosive Esophagitis and H. pylori Commercial Launch
Favorable feedback following meeting with the U.S. Food and Drug Administration (FDA) allows for planned resubmission of erosive esophagitis new drug application (NDA) this quarter Combined commercial launch of vonoprazan for erosive esophagitis and H. pylori indications expected Q4 2023, if approved FLORHAM PARK, N.J., April 04, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical... Read More
February 28, 2023
Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Meeting scheduled in March 2023 with the U.S. Food and Drug Administration (FDA) to discuss stability data and resubmission requirements for erosive GERD and H. pylori New Drug Applications FLORHAM PARK, N.J., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today reported... Read More
February 9, 2023
Phathom Pharmaceuticals Provides Regulatory Updates
FLORHAM PARK, N.J., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, today announced regulatory updates for its approved products, VOQUEZNA™ TRIPLE PAK™ and VOQUEZNA DUAL PAK™, approved in the U.S. for the treatment of H. pylori infection, and its pending New Drug Application... Read More
January 8, 2023
Phathom Pharmaceuticals Announces Positive Topline Results from Phase 3 PHALCON-NERD-301 Trial Evaluating Daily Dosing of Vonoprazan for Symptomatic Non-Erosive Gastroesophageal Reflux Disease (NERD)
Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn free days as compared to placebo (p<0.0001) Data expected to provide the basis for future regulatory submission for vonoprazan as a daily treatment for patients with NERD, pending completion of 20-week safety extension period Over 45 million people in the U.S. are estimated to... Read More
January 3, 2023
Phathom Pharmaceuticals Provides Update on New Drug Application Review of Vonoprazan for Erosive Esophagitis
FLORHAM PARK, N.J., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases and disorders, today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that no action will be taken on the Company’s new drug application (NDA) for vonoprazan, a novel... Read More

COPYRIGHT ©2023 HEALTH STOCKS HUB

  Research Tools
  News & Announcements
  Popular Topics
  Miscellaneous